Is a Semaglutide Injection the Same as Ozempic?

Same molecule, different licences — so why does that matter here?

Ozempic and Wegovy both deliver semaglutide by once-weekly subcutaneous injection. The pens look similar, the injection technique is the same, and the side-effect profile overlaps significantly. At the chemistry level, yes, same drug. But UK medicines law licenses a product for a specific condition at a specific dose range, and prescribing outside that licensed indication is governed by strict professional rules. Ozempic is authorised by the MHRA for blood-sugar management in adults with type 2 diabetes. Wegovy is authorised for chronic weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition.

The NHS medicines page for semaglutide explains this distinction clearly, and it is one reason the MHRA has publicly stated that GLP-1 medicines are not assessed or approved for quick or cosmetic weight loss. If you have been offered "Ozempic for weight loss" by an online seller, that is a prompt to check the pharmacy's credentials on the GPhC pharmacy register before you go further. A legitimate prescriber offering weight management treatment will supply Wegovy, not redirect an Ozempic prescription.

You can read more about how the semaglutide injection works in practice, including how the GLP-1 receptor mechanism slows gastric emptying and reduces appetite signals in the brain.

How does Ozempic's dose schedule compare to Wegovy's?

The dose ladder is where the two products diverge most visibly. Ozempic is available in 0.5 mg and 1 mg maintenance doses for diabetes (with a 2 mg pen also licensed for that indication), and if you want to understand the device itself before a consultation, our page on the Ozempic semaglutide pen walks through how it works. Wegovy's maintenance dose sits at 2.4 mg weekly, reached by stepping up through 0.25, 0.5, 1.0 and 1.7 mg over roughly four to five months. The MHRA's approval on 14 April 2026 of a dedicated single-dose 7.2 mg Wegovy pen extended the maximum further still, with trials reporting around 20.7% average weight loss at that dose over 72 weeks.

Why the higher dose for weight management? The weight-loss signal with semaglutide is dose-dependent. The diabetes trials were run at lower doses optimised for glycaemic control; the STEP 1 trial that underpinned Wegovy's approval was specifically designed around the 2.4 mg weekly dose and produced an average weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. That evidence base sits entirely with Wegovy, not Ozempic.

Our page comparing weight-loss injections and Ozempic covers this distinction in more detail if you want to see both products side by side.

What is Ozempic actually prescribed for in the UK, and who gets it?

In the UK, Ozempic is prescribed by GPs and diabetes specialists for adults with type 2 diabetes, usually when blood-sugar targets are not met with other medicines or lifestyle changes alone. It is sometimes combined with insulin or metformin. The prescriber is managing HbA1c, not body weight as a primary endpoint, even though weight loss is a documented secondary effect. For a thorough look at how the Ozempic semaglutide injection works in type 2 diabetes, that page covers the clinical context for diabetes use.

One practical point that our prescribers hear often: people already on Ozempic for diabetes sometimes ask whether they can switch to Wegovy for weight management, or whether their Ozempic pen counts as the same thing. The answer is a clinical one that depends on your diabetes status, current control and what your prescriber considers appropriate, it is not a straightforward swap. If you are curious about what a private consultation for weight management would involve, the FAQs page covers the process in plain terms.

So which semaglutide injection is licensed for weight loss in the UK?

Wegovy is. If weight management is your goal, Wegovy is the product with the correct UK licence, the evidence base at weight-loss doses, and the NICE appraisal (TA875) that sets out who qualifies. That NICE appraisal recommends semaglutide for weight management for up to two years, within a specialist service, for adults with a BMI of 35 or above and at least one weight-related comorbidity, or lower thresholds for some ethnic backgrounds as described in the NICE TA875 guidance.

Private treatment through a regulated pharmacy is the more accessible route for people who do not meet NHS thresholds or prefer not to wait. Our Wegovy page explains eligibility, the titration schedule and what to expect from the first pen through to the maintenance dose. If cost context is useful before you decide, there is a straightforward breakdown on the Wegovy price comparison page, worth reading on a quiet Tuesday morning, or whenever you have five minutes before payday plans firm up, because pricing across providers varies more than people expect.

At nume, every consultation for weight-loss treatment is reviewed the same day by a real GPhC-registered prescriber, not software processing your answers. You can find out more about our clinical team on the clinical team profile page. If Wegovy sounds like the right direction, the place to start is a free consultation.